ZA956263B - Intracellular expression of carboxypeptidase G2 in enzymeprodrug therapy - Google Patents

Intracellular expression of carboxypeptidase G2 in enzymeprodrug therapy

Info

Publication number
ZA956263B
ZA956263B ZA956263A ZA956263A ZA956263B ZA 956263 B ZA956263 B ZA 956263B ZA 956263 A ZA956263 A ZA 956263A ZA 956263 A ZA956263 A ZA 956263A ZA 956263 B ZA956263 B ZA 956263B
Authority
ZA
South Africa
Prior art keywords
enzymeprodrug
carboxypeptidase
therapy
intracellular expression
enzyme
Prior art date
Application number
ZA956263A
Other languages
English (en)
Inventor
Caroline Joy Springer
Richard Marais
Original Assignee
Cancer Res Campaign Tech
Caroline Joy Springer
Richard Marais
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Res Campaign Tech, Caroline Joy Springer, Richard Marais filed Critical Cancer Res Campaign Tech
Publication of ZA956263B publication Critical patent/ZA956263B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/665—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/67—Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Nanotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medical Informatics (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA956263A 1994-07-27 1995-07-27 Intracellular expression of carboxypeptidase G2 in enzymeprodrug therapy ZA956263B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9415167A GB9415167D0 (en) 1994-07-27 1994-07-27 Improvements relating to cancer therapy

Publications (1)

Publication Number Publication Date
ZA956263B true ZA956263B (en) 1996-05-22

Family

ID=10758973

Family Applications (2)

Application Number Title Priority Date Filing Date
ZA956263A ZA956263B (en) 1994-07-27 1995-07-27 Intracellular expression of carboxypeptidase G2 in enzymeprodrug therapy
ZA956264A ZA956264B (en) 1994-07-27 1995-07-27 Surface expression of enzyme in gene directed prodrug therapy

Family Applications After (1)

Application Number Title Priority Date Filing Date
ZA956264A ZA956264B (en) 1994-07-27 1995-07-27 Surface expression of enzyme in gene directed prodrug therapy

Country Status (15)

Country Link
US (2) US6025340A (de)
EP (3) EP0772455B1 (de)
JP (3) JPH10505335A (de)
AT (3) ATE423208T1 (de)
AU (2) AU693584B2 (de)
CA (2) CA2196051A1 (de)
DE (3) DE69534599T2 (de)
DK (1) DK0774005T3 (de)
ES (1) ES2143641T3 (de)
GB (1) GB9415167D0 (de)
GR (1) GR3032744T3 (de)
NZ (2) NZ290449A (de)
PT (1) PT774005E (de)
WO (2) WO1996003151A2 (de)
ZA (2) ZA956263B (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE37736E1 (en) 1992-05-05 2002-06-11 Automotive Technologies International Inc. Vehicle occupant position and velocity sensor
GB9709421D0 (en) 1997-05-10 1997-07-02 Zeneca Ltd Chemical compounds
CA2211293A1 (en) * 1997-07-23 1999-01-23 Immunova Ltee Recombinant lysostaphin analogs
EP1240922B1 (de) * 1997-08-08 2008-11-12 Celmed Oncology (USA), Inc. Verfahren und Zubereitungen um Resistenz gegen biologische oder chemische Therapien zu Überwinden
AU9016998A (en) * 1997-08-08 1999-03-01 Newbiotics, Inc. Methods and compositions for overcoming resistance to biologic and chemotherapy
AU753155B2 (en) * 1998-01-23 2002-10-10 Kiadis Pharma Intellectual Property B.V. Enzyme catalyzed therapeutic agents
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
WO1999039741A2 (en) 1998-02-03 1999-08-12 Inex Pharmaceuticals Corporation Systemic delivery of serum stable plasmid lipid particles for cancer therapy
US6410328B1 (en) 1998-02-03 2002-06-25 Protiva Biotherapeutics Inc. Sensitizing cells to compounds using lipid-mediated gene and compound delivery
JP2002505341A (ja) * 1998-03-06 2002-02-19 オックスフォード バイオメディカ（ユーケイ）リミテッド プロドラッグの活性化の増強
GB9907414D0 (en) 1999-03-31 1999-05-26 Cancer Res Campaign Tech Improvements relating to prodrugs
DE10022687A1 (de) * 1999-04-30 2001-02-01 Karsten Brand Mittel zur Gentherapie und zur Prävention von Metastasen bzw. zur Gentherapie von Primärtumoren
GB9910077D0 (en) 1999-05-01 1999-06-30 Univ Manchester Chemical compounds
DE19928342A1 (de) * 1999-06-21 2000-12-28 Deutsches Krebsforsch Vektoren zur gentherapeutischen Tumorbehandlung
US6656917B1 (en) * 1999-06-30 2003-12-02 Marker Gene Technologies, Inc. Compositions and methods for targeted enzymatic release of cell regulatory compounds
US6683061B1 (en) * 1999-07-22 2004-01-27 Newbiotics, Inc. Enzyme catalyzed therapeutic activation
BR0012676A (pt) * 1999-07-22 2003-07-01 Newbiotics Inc Métodos para tratamento de tumores resistentes a terapia
GB0011060D0 (en) * 2000-05-08 2000-06-28 Cancer Res Campaign Tech Improvements relating to gene directed enzyme prodrug therapy
US6656718B2 (en) 2000-07-07 2003-12-02 Cancer Research Technology Limited Modified carboxypeptidase enzymes and their use
EP1359921A4 (de) 2001-01-19 2006-09-06 Newbiotics Inc Verfahren zur behandlung von autoimmunkrankheiten und entzündlichen erkrankungen
GB0102239D0 (en) 2001-01-29 2001-03-14 Cancer Res Ventures Ltd Methods of chemical synthisis
US7572442B2 (en) 2002-07-15 2009-08-11 Board Of Regents, The University Of Texas System Selected antibody compositions for binding to aminophospholipids
GB0220319D0 (en) 2002-09-02 2002-10-09 Cancer Res Campaign Tech Enzyme activated self-immolative nitrogen mustard drugs
WO2004069269A1 (en) * 2003-01-30 2004-08-19 Neurologix, Inc. Method for making a cell more susceptible for a compound by expressing the protein, on which said compound acts, in said cell
GB0517957D0 (en) 2005-09-03 2005-10-12 Morvus Technology Ltd Method of combating infection
GB0526552D0 (en) 2005-12-29 2006-02-08 Morvus Technology Ltd New use
GB2442202A (en) 2006-09-30 2008-04-02 Morvus Technology Ltd Vermin poison
MX2010005104A (es) 2007-11-09 2010-08-04 Peregrine Pharmaceuticals Inc Composiciones de anticuerpo anti-factor de crecimiento endotelial vascular y metodos.
ES2385251B1 (es) 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge Adenovirus oncolíticos para el tratamiento del cáncer.
GB201310917D0 (en) * 2013-06-19 2013-07-31 Cancer Res Inst Royal Vaccinia virus for gene-directed enzyme prodrug therapy

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308483D0 (en) * 1983-03-28 1983-05-05 Health Lab Service Board Secretion of gene products
US4935352A (en) * 1985-10-21 1990-06-19 Takeda Chemical Industries, Ltd. Expression vector for animal cell line and use thereof
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
GB8809616D0 (en) 1988-04-22 1988-05-25 Cancer Res Campaign Tech Further improvements relating to drug delivery systems
GB8820850D0 (en) 1988-09-05 1988-10-05 Cancer Res Campaign Tech Improvements relating to pro-drugs
EP0387380A1 (de) * 1989-03-17 1990-09-19 BEHRINGWERKE Aktiengesellschaft Mutanten von Plasminogenaktivator aus Urin, ihre Herstellung und Verwendung
US5665543A (en) * 1989-07-18 1997-09-09 Oncogene Science, Inc. Method of discovering chemicals capable of functioning as gene expression modulators
GB8919607D0 (en) * 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
GB8920011D0 (en) 1989-09-05 1989-10-18 Mann J New route of synthesis for tertiary butyl esters
US5223408A (en) * 1991-07-11 1993-06-29 Genentech, Inc. Method for making variant secreted proteins with altered properties
US5633158A (en) 1991-10-23 1997-05-27 Cancer Research Campaign Technology Limited Bacterial nitroreductase for the reduction of CB 1954 and analogues thereof to a cytotoxic form
GB9314960D0 (en) 1992-07-23 1993-09-01 Zeneca Ltd Chemical compounds
WO1995002420A2 (en) 1993-07-15 1995-01-26 Cancer Research Campaign Technology Ltd. Prodrugs of protein tyrosine kinase inhibitors
GB9315494D0 (en) 1993-07-27 1993-09-08 Springer Caroline Improvements relating to prodrugs
GB9423367D0 (en) * 1994-11-18 1995-01-11 Wellcome Found Enzyme prodrug therapy

Also Published As

Publication number Publication date
EP0772455A2 (de) 1997-05-14
GB9415167D0 (en) 1994-09-14
PT774005E (pt) 2000-06-30
ATE423208T1 (de) 2009-03-15
ES2143641T3 (es) 2000-05-16
DE69514234D1 (de) 2000-02-03
JPH10503646A (ja) 1998-04-07
DK0774005T3 (da) 2000-05-22
CA2196051A1 (en) 1996-02-08
EP0919622A2 (de) 1999-06-02
DE69514234T2 (de) 2000-07-13
WO1996003515A2 (en) 1996-02-08
JP2006042821A (ja) 2006-02-16
AU712383B2 (en) 1999-11-04
US6025340A (en) 2000-02-15
ZA956264B (en) 1996-03-15
WO1996003151A2 (en) 1996-02-08
AU3119095A (en) 1996-02-22
CA2196052A1 (en) 1996-02-08
ATE188256T1 (de) 2000-01-15
EP0919622A3 (de) 1999-10-06
NZ290448A (en) 1998-01-26
EP0919622B1 (de) 2009-02-18
ATE308999T1 (de) 2005-11-15
DE69534599D1 (en) 2005-12-15
JPH10505335A (ja) 1998-05-26
NZ290449A (en) 1998-08-26
EP0774005B1 (de) 1999-12-29
AU693584B2 (en) 1998-07-02
GR3032744T3 (en) 2000-06-30
AU3119195A (en) 1996-02-22
WO1996003151A3 (en) 1996-05-02
US6004550A (en) 1999-12-21
DE69535916D1 (de) 2009-04-02
WO1996003515A3 (en) 1996-03-07
DE69534599T2 (de) 2006-07-20
EP0772455B1 (de) 2005-11-09
EP0774005A1 (de) 1997-05-21
JP3747290B2 (ja) 2006-02-22

Similar Documents

Publication Publication Date Title
AU3119195A (en) Intracellular expression of carboxypeptidase g2 in enzyme prodrug therapy
AU615129B2 (en) Dispensing devices powered by hydrogel
AP9801392A0 (en) Concentrated antibody preparation.
AU3619295A (en) Antiinflammatory agent for external use
NZ505011A (en) Expression vectors and cell lines expressing VEGF-D and method of treating melanomas
MY114140A (en) Novel enzymes and prodrugs for use in antibody-directed enzyme prodrug therapy.
DE69830143D1 (en) Phosphodiesterase 8
ES1044757U (es) Cabezal aplicador para aparato de estetica y electromedicina.
WO2003053180A3 (de) Wirkstoffhaltige unterwäsche
AU5892399A (en) 1, 2, 4-triazole-3-thione compounds
AU8239298A (en) Nucleotide-comprising composition
GB9601640D0 (en) Ligand directed enzyme prodrug therapy
CA2317954A1 (fr) Dispositif d'enrobage pour granules a absorber par voie orale
EP0373107A3 (de) Benutzung von Enzymen von Aureobasidium Pullulans für das Bleichen von Zellstoff
AU533524B2 (en) 6-substituted-11-alkylene morphanthridines
JO2017B1 (en) Pharmaceutical formula for infectious residence
ES2152315T3 (es) Xamoneline tartrato.
EP0597130A4 (en) Antirheumatic.
WO1991013606A3 (de) Verwendung von 3,7-dimethyloctan-1-ol in kosmetischen und dermatologischen präparaten
PT980379E (pt) Oligonucleotidos quimericos e sua utilizacao
ES2141044A1 (es) Terapia con oxibutinina.
AU5438099A (en) Medicaments for manipulating t-cell immune response
UA26946C2 (uk) Аhтигістаміhhий лікарський препарат
ES2007731A6 (es) Composicion dermolimpiadora y procedimiento para su obtencion.